Equitable Holdings Inc. Acquires New Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Posted by Stanley Muller on Aug 29th, 2026

Equitable Holdings Inc. bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 2,920 shares of the pharmaceutical company’s stock, valued at approximately $1,451,000.

Several other large investors have also recently bought and sold shares of the company. Summit Global Investments acquired a new stake in Vertex Pharmaceuticals in the second quarter valued at approximately $3,568,000. Allworth Financial LP lifted its position in shares of Vertex Pharmaceuticals by 414.1% during the 4th quarter. Allworth Financial LP now owns 14,036 shares of the pharmaceutical company’s stock valued at $6,363,000 after buying an additional 11,306 shares in the last quarter. Calamos Advisors LLC lifted its position in shares of Vertex Pharmaceuticals by 77.1% during the 1st quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company’s stock valued at $34,779,000 after buying an additional 33,917 shares in the last quarter. Sandro Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals in the 4th quarter valued at $1,436,000. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. grew its stake in Vertex Pharmaceuticals by 11.9% in the 1st quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 34,991 shares of the pharmaceutical company’s stock valued at $15,625,000 after acquiring an additional 3,710 shares during the period. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Down 1.1%

Shares of VRTX opened at $541.69 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $374.17 and a 52-week high of $555.69. The stock has a market cap of $137.48 billion, a PE ratio of 31.53, a price-to-earnings-growth ratio of 2.38 and a beta of 0.30. The firm’s fifty day moving average is $502.08 and its two-hundred day moving average is $468.67.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 EPS for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). The business had revenue of $3.33 billion during the quarter, compared to analyst estimates of $3.23 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. Vertex Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the company earned $4.52 earnings per share. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.86 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on VRTX. Canaccord Genuity Group upped their price objective on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a “hold” rating in a research report on Tuesday, August 4th. Truist Financial boosted their target price on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. Royal Bank Of Canada raised their price target on shares of Vertex Pharmaceuticals from $543.00 to $570.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Finally, UBS Group boosted their price objective on Vertex Pharmaceuticals from $545.00 to $585.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $563.50.

View Our Latest Report on Vertex Pharmaceuticals

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Duncan Mckechnie sold 1,541 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total transaction of $799,779.00. Following the transaction, the executive vice president directly owned 11,001 shares in the company, valued at $5,709,519. The trade was a 12.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the sale, the executive vice president owned 45,321 shares of the company’s stock, valued at $23,793,071.79. This trade represents a 3.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 10,464 shares of company stock worth $4,959,397. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.